Monitor upcoming FDA End-of-Phase 2 meeting for VCN-01 in PDAC in 1H 2026, which could de-risk the pivotal trial design. The SYN-020 licensing deal de-risks development costs but removes a potential pipeline asset.
TOVX drugs
TOVX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 12 $0.1800entry
- T+1 · 8mo ago 0.00%α +0.60% · $0.1800
- T+5 · 8mo ago +5.56%α +6.53% · $0.1900
- T+20 · 7mo ago +27.78%α +25.80% · $0.2300
- T+60 · 5mo ago +44.44%α +33.75% · $0.2600
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theriva Biologics reported its 2025 financial results, highlighted by a $9.0 million contingent consideration charge tied to VCN-01's Phase 2b trial success, reduced R&D spending, and a licensing deal for SYN-020 that brings $300,000 upfront and up to $38 million in potential milestones. The company has $15.2 million in cash as of February 2026, providing runway into Q1 2027.
Key Financial Metrics
Key Facts
- VCN-01 achieved primary survival and safety endpoints in Phase 2b trial, triggering a $9.0 million contingent consideration expense
- Licensed SYN-020 to Rasayana Therapeutics for $300k upfront, up to $38M in milestones, and tiered single-digit royalties
- R&D expenses decreased 28% YoY to $8.6M due to trial completions
- General and administrative expenses doubled to $15.4M, driven by the contingent consideration adjustment
- Cash balance increased to $15.2M as of February 26, 2026, funding operations into Q1 2027
- Audited financials include a going concern qualification from auditors
Financial Impact
Net loss attributable to common stockholders was $25.2M in 2025 vs $25.7M in 2024; $9.0M non-cash charge from VCN-01 trial success inflated G&A expenses
Risk Factors
- Going concern qualification in audited financials indicates liquidity risk despite current cash runway
- Heavy reliance on successful clinical development of VCN-01 with no near-term revenue prospects
- Market cap of $8M appears disconnected from fundamentals given lack of revenue and ongoing losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254568 |
Track record
11 reports on TOVX
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
- Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
- Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
- Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
- Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
- Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers